A novel solid-phase synthesis of 5'-radiolabeled oligonucleotides is described. The labeling reaction is carried out by the phosphoramidite method with the aid of [4,6-di-14C]-5'-dimethoxytritylthymidine building block 1. The feasibility of the method is demonstrated by preparation of 3'-phosphorylated dodecathymidylate phosphorothioate containing radiolabeled nucleoside at the 5'-terminus.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0960-894x(98)00028-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Absorption, metabolism, and excretion of oral [C] radiolabeled donafenib: an open-label, phase I, single-dose study in humans.
Cancer Chemother Pharmacol
December 2024
Department of Pharmacy, The First Affiliated Hospital of Soochow University, Suzhou, 215031, China.
Purpose: The study aims to investigate the absorption, metabolism, and excretion of donafenib, a deuterated derivative of sorafenib, in healthy Chinese male volunteers.
Methods: Six healthy Chinese male volunteers were administered a single oral dose of 300 mg donafenib containing 120 µCi of [14 C]-donafenib. The study involved collecting and analyzing plasma, urine, and feces samples to determine the recovery and distribution of total radioactivity, identify metabolites, and assess the metabolic pathways of donafenib.
Absorption, distribution, metabolism, and excretion of tirzepatide in humans, rats, and monkeys.
Eur J Pharm Sci
November 2024
Eli Lilly and Company, Indianapolis, USA.
Tirzepatide is a once-weekly GIP/GLP-1 receptor agonist used for treatment of type 2 diabetes (T2D) in adults and was recently approved for treatment of obesity. To determine the absorption, distribution, metabolism, and excretion (ADME) of tirzepatide, [C]-radiolabeled tirzepatide was investigated in both humans and preclinical species. [C]-Tirzepatide was prepared by incorporating four C's in the linker region between the amino acid backbone and the di-acid moiety.
View Article and Find Full Text PDFA Phase I Study To Determine the Absolute Bioavailability and Absorption, Distribution, Metabolism, and Excretion of Capivasertib in Healthy Male Participants.
Drug Metab Dispos
August 2024
Clinical Pharmacology and Quantitative Pharmacology, BioPharmaceuticals R&D (C.M.), Drug Metabolism and Pharmacokinetics, Oncology R&D (M.W.), Global Medicines Development, Oncology R&D (R.S., D.S.), Integrated Bioanalysis, BioPharmaceuticals R&D (C.B.), and Pharmaceutical Sciences, R&D (R.A.B., M.G.), AstraZeneca, Cambridge, United Kingdom; Drug Metabolism and Pharmacokinetics, Oncology R&D (Z.Z.) and Clinical Pharmacology and Quantitative Pharmacology, BioPharmaceuticals R&D (J.D.), AstraZeneca, Waltham, Massachusetts; Quotient Sciences Ltd, Ruddington, Nottingham, United Kingdom (S.S.); and Clinical Pharmacology and Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.C.)
Article Synopsis
- * Participants received oral and intravenous doses, with results showing a median maximum concentration at 1.7 hours and an elimination half-life of 12.9 hours.
- * The study found that about 28.6% of the drug was absorbed, with the main metabolic product being M11, and no significant safety issues were reported.
A phase 1 open label study to assess the human mass balance and metabolite profile of C-fosmanogepix, a novel Gwt-1 inhibitor in healthy male participants.
Antimicrob Agents Chemother
August 2024
Pfizer Inc., New York, New York, USA.
Article Synopsis
- FMGX, a novel antifungal compound, is being tested for treating invasive fungal infections, with a Phase 1 study examining its metabolism in ten healthy males through oral and intravenous administration.
- The results showed that FMGX is eliminated primarily through urine and feces, with a substantial percentage of the radioactivity being recovered post-dose in both cohorts, indicating effective renal and hepatic elimination routes.
- No serious adverse effects were reported during the study, and the metabolic pathways observed in humans were consistent with those in animal studies, suggesting a safe profile for further investigation.
Preclinical Pharmacokinetics in Tumors and Normal Tissues of the Antigene PNA Oligonucleotide MYCN-Inhibitor BGA002.
Nucleic Acid Ther
August 2024
Department of Pharmacy and Biotechnologies, University of Bologna, Bologna, Italy.
Although has been considered an undruggable target, alterations confer poor prognosis in many pediatric and adult cancers. The novel -specific inhibitor BGA002 is an antigene peptide nucleic acid oligonucleotide covalently bound to a nuclear localization signal peptide. In the present study, we characterized the pharmacokinetics (PK) of BGA002 after single and repeated administration to mice using a novel specific enzyme-linked immunosorbent assay.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!